Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients SK Kumar, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, S Pandey, ... Leukemia 28 (5), 1122-1128, 2014 | 1505 | 2014 |
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis TV Kourelis, SK Kumar, MA Gertz, MQ Lacy, FK Buadi, SR Hayman, ... Journal of clinical oncology 31 (34), 4319, 2013 | 243 | 2013 |
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma P Kapoor, SK Kumar, A Dispenzieri, MQ Lacy, F Buadi, D Dingli, ... Journal of Clinical Oncology 31 (36), 4529, 2013 | 209 | 2013 |
Smoldering multiple myeloma requiring treatment: time for a new definition? A Dispenzieri, AK Stewart, A Chanan-Khan, SV Rajkumar, RA Kyle, ... Blood, The Journal of the American Society of Hematology 122 (26), 4172-4181, 2013 | 114 | 2013 |
Pomalidomide MQ Lacy, AR McCurdy Blood, The Journal of the American Society of Hematology 122 (14), 2305-2309, 2013 | 104 | 2013 |
Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience M Grogan, M Gertz, A McCurdy, L Roeker, R Kyle, S Kushwaha, R Daly, ... World journal of transplantation 6 (2), 380, 2016 | 66 | 2016 |
Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both L Zand, SH Nasr, MA Gertz, A Dispenzieri, MQ Lacy, FK Buadi, S Kumar, ... Leukemia & lymphoma 56 (12), 3357-3364, 2015 | 58 | 2015 |
Myelomatous involvement of the central nervous system J Paludo, U Painuly, S Kumar, WI Gonsalves, V Rajkumar, F Buadi, ... Clinical Lymphoma Myeloma and Leukemia 16 (11), 644-654, 2016 | 49 | 2016 |
When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer MS Hasim, M Marotel, JJ Hodgins, E Vulpis, OJ Makinson, S Asif, HY Shih, ... Science Advances 8 (15), eabj3286, 2022 | 47 | 2022 |
Consensus guidelines on the diagnosis of multiple myeloma and related disorders: recommendations of the myeloma Canada research network consensus guideline consortium DJ Bergstrom, R Kotb, ML Louzada, HJ Sutherland, S Tavoularis, ... Clinical Lymphoma Myeloma and Leukemia 20 (7), e352-e367, 2020 | 45 | 2020 |
Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT SV Glavey, MA Gertz, A Dispenzieri, S Kumar, F Buadi, M Lacy, ... Bone marrow transplantation 48 (12), 1543-1547, 2013 | 41 | 2013 |
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma G Srivastava, V Rana, MQ Lacy, FK Buadi, SR Hayman, A Dispenzieri, ... Leukemia 27 (10), 2062-2066, 2013 | 40 | 2013 |
Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist AR McCurdy, MQ Lacy Therapeutic Advances in Hematology 4 (3), 211-216, 2013 | 40 | 2013 |
Implications of continued response after autologous stem cell transplantation for multiple myeloma WI Gonsalves, MA Gertz, A Dispenzieri, MQ Lacy, Y Lin, PP Singh, ... Blood, The Journal of the American Society of Hematology 122 (10), 1746-1749, 2013 | 29 | 2013 |
Part 1 results of a dose-finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM) S Trudel, A McCurdy, HJ Sutherland, ML Louzada, CP Venner, HS Mian, ... Blood 138, 1653, 2021 | 23 | 2021 |
Monoclonal protein reference change value as determined by gel-based serum protein electrophoresis M Salamatmanesh, CR McCudden, A McCurdy, RA Booth Clinical biochemistry 51, 61-65, 2018 | 19 | 2018 |
Part 1 results of a dose finding study of belantamab mafodotin (GSK2857916) in combination with pomalidomide (POM) and dexamethasone (DEX) for the treatment of relapsed … S Trudel, A McCurdy, H Sutherland, ML Louzada, CP Venner Blood 136 (Suppl 1), 725, 2020 | 18 | 2020 |
Synoptic reporting for protein electrophoresis and immunofixation CR McCudden, RA Booth, DCC Lin, A McCurdy, N Rupani, A Kew Clinical Biochemistry 51, 21-28, 2018 | 18 | 2018 |
Selinexor in combination with bortezomib and dexamethasone (SdB) demonstrates significant activity in patients with refractory multiple myeloma (MM) including proteasome … NJ Bahlis, R Kotb, M Sebag, HJ Sutherland, R LeBlanc, D White, ... Blood 128 (22), 977, 2016 | 17 | 2016 |
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review H Mian, A McCurdy, S Giri, S Grant, B Rochwerg, E Winks, AE Rosko, ... Blood cancer journal 13 (1), 6, 2023 | 16 | 2023 |